Boston Partners’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Boston Partners’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-285,530	Closed	-$971K	–	773
2018 Q3	$971K	Sell	285,530 -7,574	-3%	-$27.3K	﹤0.01%	668
2018 Q2	$1.1M	Buy	293,104 +36,544	+14%	+$178K	﹤0.01%	733
2018 Q1	$1.05M	Sell	256,560 -152,491	-37%	-$710K	﹤0.01%	694
2017 Q4	$1.9M	Hold	409,051	–	–	﹤0.01%	672
2017 Q3	$2.9M	Hold	409,051	–	–	﹤0.01%	616
2017 Q2	$2.96M	Hold	409,051	–	–	﹤0.01%	596
2017 Q1	$2.52M	Hold	409,051	–	–	﹤0.01%	633
2016 Q4	$2.4M	Hold	409,051	–	–	﹤0.01%	652
2016 Q3	$2.17M	Buy	+409,051	New	+$2.21M	﹤0.01%	651

Boston Partners's KERX Position: Q4 2018 in Review

Boston Partners sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 285,530 shares — an estimated $971K sold.

Boston Partners first reported a position in KERX in Q3 2016 and held it in 9 quarters. The position peaked at $2.96M in Q2 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

Boston Partners reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
Boston Partners sold 285,530 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $971K.
Boston Partners first reported a position in Keryx Biopharmaceuticals Inc in Q3 2016 and held it in 9 quarters.
Boston Partners's Keryx Biopharmaceuticals Inc position peaked at $2.96M in Q2 2017.
1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Boston Partners's 13F filing for Q4 2018, filed 7 Feb 2019.